文献速递母胎医学产科

早孕期联合筛查与侵入性诊断对非典型染色体异常的丹麦全国研究:产前筛查特征及与NIPT检测的比较

Combined first-trimester screening and invasive diagnostics for atypical chromosomal aberrations: Danish nationwide study of prenatal profiles and detection compared with NIPT.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-09-04

该丹麦全国回顾性研究纳入2008年1月1日至2018年12月31日接受早孕期联合筛查(cFTS)的565708例孕妇,分析非典型染色体异常(尤其致病性拷贝数变异pCNV)的产前筛查特征。cFTS对常见三体的检出率为87%,但对pCNV仅23%筛查阳性,51%的pCNV在出生后才诊断。若对高风险孕妇用常规NIPT替代侵入性检测,27%的致病性异常会被漏诊。

要点

  • cFTS检出87%常见三体,对三倍体86%、单体X 92%、其他性染色体异常58%、罕见常染色体三体或嵌合体70%检出。
  • pCNV占全部染色体异常的27%(n=1091),仅23%的pCNV经cFTS筛查阳性,51%在出生后才诊断。
  • 高风险孕妇中pCNV占诊断异常的14%;常规NIPT会漏诊27%的致病性异常,即1/26高风险孕妇虽NIPT正常但仍有染色体异常。

核心结论

  • 作为21、18、13三体筛查的副产品,多数三倍体、大部分非典型性染色体异常、罕见常染色体三体和嵌合体可在产前检出,但仅23%的pCNV与cFTS高风险相关且仅半数在产前诊断。
  • 对高风险孕妇用NIPT替代侵入性检测将大幅降低早孕期致病性染色体异常的检出。

研究设计与样本

  • 丹麦全国回顾性研究,基于丹麦胎儿医学数据库,纳入2008年1月1日至2018年12月31日期间接受cFTS和21三体风险评分的所有孕妇,共565708例。
  • 染色体异常分为六类:三倍体、常见三体(13、18或21)、单体X、其他性染色体异常、pCNV、罕见常染色体三体或嵌合体。

主要发现

  • 3982例(0.70%)诊断胎儿染色体异常;cFTS检出87%常见三体、86%三倍体、92%单体X、58%非典型性染色体异常、70%罕见常染色体三体或嵌合体。
  • pCNV占全部诊断染色体异常的27%(n=1091),研究期间患病率随产前CMA应用增加而上升。
  • 孕妇年龄<30岁、颈项透明层厚度≤第95百分位、PAPP-A≥1中位数倍数或21三体风险≤1/1000时,pCNV患病率显著超过21、18、13三体患病率。
  • pCNV妊娠相比未受累妊娠,颈项透明层显著增厚, maternal血清标志物PAPP-A和β-hCG水平显著降低;但仅23%的pCNV经cFTS筛查阳性,51%出生后才诊断。
  • 高风险妊娠中pCNV占诊断异常的14%;常规NIPT(筛查21、18、13三体和单体X)会漏诊27%的侵入性检测诊断的致病性异常,即1/26高风险孕妇NIPT正常但仍有染色体异常。

临床怎么用

  • cFTS作为21、18、13三体筛查可附带检出多数三倍体、非典型性染色体异常、罕见常染色体三体和嵌合体。
  • 对cFTS高风险孕妇,用常规NIPT替代侵入性CMA会漏诊27%的致病性异常,包括仅23%pCNV经cFTS筛查阳性且51%出生后才诊断的情况。
  • 中间风险组(21三体风险1/100-299)采用NIPT的 contingent 筛查模型会漏诊50%的异常;79%的pCNV<5Mb,现有全基因组NIPT无法检出。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our aim was to examine the prenatal profiles of pregnancies affected by an atypical chromosomal aberration, focusing on pathogenic copy-number variants (pCNVs). We also wanted to quantify the performance of combined first-trimester screening (cFTS) and a second-trimester anomaly scan in detecting these aberrations. Finally, we aimed to estimate the consequences of a policy of using non-invasive prenatal testing (NIPT) rather than invasive testing with chromosomal microarray analysis (CMA) to manage pregnancies identified as high risk by cFTS. METHODS: This was a retrospective review of the Danish Fetal Medicine Database of all pregnant women who underwent cFTS and a risk assessment for trisomy 21 between 1 January 2008 and 31 December 2018. Chromosomal aberrations diagnosed prenatally, postnatally or from fetal tissue following pregnancy loss or termination of pregnancy were identified. Chromosomal aberrations were grouped into one of six categories: triploidy; common trisomy (13, 18 or 21); monosomy X; other sex-chromosome aberration (SCA); pCNV; and rare autosomal trisomy (RAT) or mosaicism. The prevalence of each aberration category was stratified by the individual cFTS markers and trisomy 21 risk estimate, and the size of each pCNV diagnosed by CMA was calculated. RESULTS: We retrieved data on 565 708 pregnancies, of which 3982 (0.70%) were diagnosed with a fetal chromosomal aberration. cFTS identified 87% of the common trisomies, but it also performed well in identifying triploidies (86%), monosomy X (92%), atypical SCAs (58%) and RATs or mosaicisms (70%). pCNVs comprised 27% (n = 1091) of the chromosomal aberrations diagnosed overall, and the prevalence increased during the study period, as prenatal CMA was increasingly being performed. In pregnancies with a maternal age < 30 years, nuchal translucency (NT) thickness ≤ 95th centile, pregnancy-associated plasma protein-A (PAPP-A) ≥ 1 multiple of the median, or trisomy 21 risk of ≤ 1 in 1000, the prevalence of pCNVs exceeded significantly the prevalence of trisomies 21, 18 and 13. Pregnancies affected by a pCNV had significantly increased NT and decreased levels of the maternal biomarkers PAPP-A and β-human chorionic gonadotropin compared with unaffected pregnancies. However, only 23% of these pregnancies screened positive on cFTS and 51% of pCNVs were not detected until after birth. Among high-risk pregnancies, pCNVs comprised 14% of diagnosed aberrations, and when other atypical aberrations were considered, conventional NIPT (screening for trisomies 21, 18 and 13 and monosomy X) would miss 27% of all pathogenic aberrations diagnosed from invasive testing following a high-risk cFTS result. Thus, 1 in 26 pregnancies at high risk following cFTS would be affected by a chromosomal aberration despite a normal result from conventional NIPT. In a contingent screening model using NIPT for the 'intermediate'-risk group (trisomy 21 risk of 1 in 100-299), 50% of the aberrations would be missed. In our cohort, 79% of the pCNVs diagnosed were < 5Mb and therefore not detectable using current forms of 'genome-wide' NIPT. CONCLUSIONS: As a by-product of screening for trisomies 21, 18 and 13, most triploidies and the majority of atypical SCAs, RATs and mosaicisms are detected before birth. However, only 23% of pCNVs are associated with a high-risk result according to cFTS and only half are diagnosed before birth. Replacing invasive testing with NIPT for high-risk pregnancies would substantially decrease the first-trimester detection of pathogenic chromosomal anomalies. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gadsbøll K, Vogel I, Kristensen SE, et al. Combined first-trimester screening and invasive diagnostics for atypical chromosomal aberrations: Danish nationwide study of prenatal profiles and detection compared with NIPT. Ultrasound Obstet Gynecol. 2024. PMID: 38642365. doi:10.1002/uog.27667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。